5-carboxamidotryptamine has been researched along with Migraine Disorders in 4 studies
5-carboxamidotryptamine: agonist of 5-HT receptor; structure given in first source
Migraine Disorders: A class of disabling primary headache disorders, characterized by recurrent unilateral pulsatile headaches. The two major subtypes are common migraine (without aura) and classic migraine (with aura or neurological symptoms). (International Classification of Headache Disorders, 2nd ed. Cephalalgia 2004: suppl 1)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Of the prophylactic antimigraine drugs tested, methysergide and lisuride behaved as efficacious agonists (Emax > or = 90% relative to 5-HT) whereas pitozifen and (-)propranolol acted as a partial agonist (60%) and an antagonist, respectively." | 1.30 | Agonist activity of antimigraine drugs at recombinant human 5-HT1A receptors: potential implications for prophylactic and acute therapy. ( Audinot-Bouchez, V; Chaput, C; Conte, C; Lavielle, G; Lochon, S; Millan, MJ; Newman-Tancredi, A; Verrièle, L, 1997) |
| "Alniditan is a new migraine-abortive agent." | 1.29 | Alniditan, a new 5-hydroxytryptamine1D agonist and migraine-abortive agent: ligand-binding properties of human 5-hydroxytryptamine1D alpha, human 5-hydroxytryptamine1D beta, and calf 5-hydroxytryptamine1D receptors investigated with [3H]5-hydroxytryptamin ( Gommeren, W; Haegeman, G; Heylen, L; Lesage, AS; Leysen, JE; Luyten, WH; Schotte, A; Van de Weyer, I; Van Gompel, P; Vanhoenacker, P; Wouters, R, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (75.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Glen, RC | 1 |
| Martin, GR | 1 |
| Hill, AP | 1 |
| Hyde, RM | 1 |
| Woollard, PM | 1 |
| Salmon, JA | 1 |
| Buckingham, J | 1 |
| Robertson, AD | 1 |
| Leysen, JE | 1 |
| Gommeren, W | 1 |
| Heylen, L | 1 |
| Luyten, WH | 1 |
| Van de Weyer, I | 1 |
| Vanhoenacker, P | 1 |
| Haegeman, G | 1 |
| Schotte, A | 1 |
| Van Gompel, P | 1 |
| Wouters, R | 1 |
| Lesage, AS | 1 |
| Newman-Tancredi, A | 1 |
| Conte, C | 1 |
| Chaput, C | 1 |
| Verrièle, L | 1 |
| Audinot-Bouchez, V | 1 |
| Lochon, S | 1 |
| Lavielle, G | 1 |
| Millan, MJ | 1 |
| Wiedemann, M | 1 |
| Lyhs, B | 1 |
| Bartels, JP | 1 |
| Sieber, M | 1 |
4 other studies available for 5-carboxamidotryptamine and Migraine Disorders
| Article | Year |
|---|---|
Computer-aided design and synthesis of 5-substituted tryptamines and their pharmacology at the 5-HT1D receptor: discovery of compounds with potential anti-migraine properties.
Topics: Animals; Aorta; Computer-Aided Design; Drug Design; Haplorhini; In Vitro Techniques; Migraine Disord | 1995 |
Alniditan, a new 5-hydroxytryptamine1D agonist and migraine-abortive agent: ligand-binding properties of human 5-hydroxytryptamine1D alpha, human 5-hydroxytryptamine1D beta, and calf 5-hydroxytryptamine1D receptors investigated with [3H]5-hydroxytryptamin
Topics: Animals; Benzopyrans; Cattle; Cloning, Molecular; Glioma; HeLa Cells; Humans; Mice; Migraine Disorde | 1996 |
Agonist activity of antimigraine drugs at recombinant human 5-HT1A receptors: potential implications for prophylactic and acute therapy.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Benzopyrans; Binding, Competitive; Cell Membrane; C | 1997 |
The pharmacological control of neuronal excitability in the retinal spreading depression model of migraine.
Topics: Animals; Barbiturates; Chickens; Cortical Spreading Depression; Disease Models, Animal; Fructose; In | 2012 |